Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays

Coronavirus Disease 2019 (COVID-19) convalescent plasma (CCP) was approved by the FDA for use in severe cases of COVID-19 under an emergency Investigational New Drug (IND) protocol. Eligibility criteria for CCP donors includes documentation of evidence of COVID-19 either by viral RNA detection at th...

Descripción completa

Detalles Bibliográficos
Autores principales: DomBourian, Melkon G., Annen, Kyle, Huey, Leah, Andersen, Gillian, Merkel, Patricia A., Jung, Sarah, Dominguez, Samuel R., Knight, Vijaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438987/
https://www.ncbi.nlm.nih.gov/pubmed/32828791
http://dx.doi.org/10.1016/j.jim.2020.112837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438987/
https://www.ncbi.nlm.nih.gov/pubmed/32828791
http://dx.doi.org/10.1016/j.jim.2020.112837

Ejemplares similares